The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 11 October 2005, www.theannals.com, DOI 10.1345/aph.1E061.
 The Annals of Pharmacotherapy: Vol. 39, No. 11, pp. 1861-1869. DOI 10.1345/aph.1E061
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Louie, S. G.
Right arrow Articles by Gill, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Louie, S. G.
Right arrow Articles by Gill, M. A.

FORMULARY FORUM

Aralast: A New {alpha}1-Protease Inhibitor for Treatment of {alpha}-Antitrypsin Deficiency

Stan Gee Louie, PharmD

Associate Professor, Department of Pharmacy, University of Southern California, Los Angeles, CA

David Alexander Sclar, PhD

Boeing Distinguished Professor, Health Policy & Administration, Washington State University, Pullman, WA

Mark Anthony Gill, PharmD

Professor, Department of Pharmacy, University of Southern California

Reprints: Dr. Louie, Department of Pharmacy, University of Southern California, 1985 Zonal Ave., Los Angeles, CA 90089-9121, fax 323/442-1395, slouie{at}usc.edu

OBJECTIVE: To review the epidemiology, pathogenesis, and management of patients with {alpha}-antitrypsin (AAT) deficiency syndrome and compare Aralast with Prolastin, 2 of the 3 available human plasma-derived AAT agents.

DATA SOURCES: Articles were identified using a MEDLINE (1966-September 2005) search with MESH headings that included {alpha}-antitrypsin and emphysema.

STUDY SELECTION AND DATA EXTRACTION: All papers from peer-reviewed journals on the laboratory or clinical efficacy of plasma-derived AAT (eg, Prolastin, Aralast) for patients with this autosomal recessive disorder were reviewed.

DATA SYNTHESIS: Clinical trials found that AAT augmentation prevents progression of AAT-deficient emphysema and thus its associated morbidity and mortality. Treatment with Aralast has been shown to be safe and well tolerated, with a low incidence of mild to moderate adverse events. Pharmacoeconomics studies of AAT augmentation demonstrated that the use of Aralast was cost-effective as lifelong augmentation therapy for AAT-deficient emphysema.

CONCLUSIONS: Because of its effectiveness and extra safety measure compared with Prolastin, Aralast should be recommended for formulary inclusion.

Key Words: {alpha}-antitrypsin: Aralast, Prolastin; emphysema

Published Online, October 11, 2005. www.theannals.com, DOI 10.1345/aph.1E061

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-05-033-H01


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
J. H. Gemberling and M. A Finnerty
Comment: Aralast: A New {alpha}1-Protease Inhibitor for Treatment of {alpha}-Antitrypsin Deficiency
Ann. Pharmacother., April 1, 2006; 40(4): 786 - 787.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. R Petteway Jr
Comment: Comparisons of Aralast and Prolastin, {alpha}1-Protease Inhibitors for Treatment of {alpha}1-Antitrypsin Deficiency
Ann. Pharmacother., February 1, 2006; 40(2): 353 - 354.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.